Navigation Links
Boehringer Ingelheim Enrolls First Patients in Pivotal Phase 3 Interferon-Free Hepatitis C Trial Program
Date:1/17/2013

RIDGEFIELD, Conn., Jan. 17, 2013 /PRNewswire/ -- Today, Boehringer Ingelheim Pharmaceuticals, Inc. announced that the first patients have been enrolled in the company's pivotal Phase 3 interferon (IFN)-free hepatitis C (HCV) clinical trial program, HCVerso™. Boehringer Ingelheim's investigational IFN-free regimen combines the compounds faldaprevir (BI 201335), a protease inhibitor administered once-daily, and BI 207127, a non-nucleoside polymerase inhibitor administered twice-daily, plus ribavirin. Phase 3 clinical trial sites are established in more than 25 states in the U.S.

The HCVerso™ clinical trial program includes two pivotal Phase 3 IFN-free studies that will enroll approximately 1,000 treatment-naive HCV genotype-1b (GT-1b) patients, including those who are interferon eligible or ineligible. The decision to enroll GT-1b patients in the Phase 3 trials follows results from the Phase 2b SOUND-C studies, where Boehringer Ingelheim's investigational, IFN-free regimen showed higher viral cure rates* in patients with the 1b HCV genotype, the most prevalent type of HCV globally.

New preliminary results from the SOUND-C3 trial show that 100 percent (n=20) of patients with HCV GT-1b  achieved sustained virologic response four weeks (SVR4) after completing a 16 week course of treatment. Two patients experienced serious adverse events and two patients discontinued treatment early due to adverse events in SOUND-C3. Four patients in this study had compensated liver cirrhosis (damaged or scarred liver tissue). These data further support the trial design for Boehringer Ingelheim's pivotal HCVerso™ study. Full results from SOUND-C3 are expected in 2013.

"We are prou
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
2. Boehringer Ingelheim Announces Equine Research Awards
3. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
4. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
5. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
6. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
7. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
10. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
11. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... -- Research and Markets has announced the ... 2014 " report to their offering. ... a professional and in-depth study on the current state ... report provides a basic overview of the industry including ... meter market analysis is provided for both the international ...
(Date:8/26/2014)... design and architecture firm NBBJ announced today the expansion of its healthcare ... Rudy Widjaja will lead planning and design teams from NBBJ,s ... with healthcare clients in China , Taiwan ... well as the firm,s global network of healthcare experts.   ... at a time when the scope of the firm,s healthcare practice in ...
(Date:8/26/2014)... -- Research and Markets  has announced the addition ... report to their offering. Cytomegalovirus retinitis ... causative organism of this disease is cytomegalovirus, a herpes ... This disease can lead to permanent blindness if left ... the other eye if neglected. The virus is very ...
Breaking Medicine Technology:Global Glucose Meter Industry Report 2014 2Global Glucose Meter Industry Report 2014 3Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 2Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 3Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 4Leading Architectural Design Firm NBBJ Launches Healthcare Practice in China 5Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 2Global Cytomegalovirus Retinitis Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Gilead Sciences, Hospira and Shire 3
... Mo., Oct. 4 A new study by researchers ... Kansas City, Mo., found that rapid electronic review of ... allowed for earlier diagnosis and treatment of potentially serious ... American Academy of Pediatrics National Conference and Exhibition in ...
... BURLINGTON, Mass., Oct. 4 Decision Resources, one of the ... issues finds that the non-small-cell lung cancer (NSCLC) drug market ... than $6.5 billion in 2019 in the United States, France, ... Pharmacor 2010 findings from the topic entitled Non-Small-Cell Lung ...
Cached Medicine Technology:New Study Shows Telemedicine Works to Effectively Identify Heart Problems in Children Far from a Specialized Medical Center 2The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019 2The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019 3
(Date:8/27/2014)... Aspirus Wausau Hospital today announced the ... Buzz™ Digital O.R. at Aspirus Wausau Hospital, in Wausau, ... operating rooms will be Buzz, a centralized surgical hub ... supports planning, navigation, imaging and communications connectivity. , ... software and hardware all controlled from the full HD ...
(Date:8/27/2014)... 2014 BCC Research ( http://www.bccresearch.com ) ... IMPLANTS AND REGENERATIVE PRODUCTS , the global market for ... billion by 2014-end to $42.2 billion by 2019, with ... 2014 to 2019. New technologies and an increasingly older ... the market. , While there are many conventional and ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 UNIWIGS, one of the ... hair pieces, offers big deals and sales on all its products, ... hair products can save much on UniWigs hair products ... orders, they can save $10 with a coupon code LABOR10; while ... a coupon code LABOR50. Besides this deal which coupon code is ...
(Date:8/27/2014)... HealthDay Reporter TUESDAY, Aug. 26, 2014 ... for blood transfusions might also protect the brains of premature ... stimulates red blood cell production, appears to prevent brain damage ... Petra Huppi, a professor of pediatrics and newborn medicine at ... of whether EPO protects the brains of these children will ...
(Date:8/27/2014)... Hepatocellular carcinoma (HCC) is the second leading cause ... are due to the difficulty in treating this ... epirubicin, cisplatin, 5-fluorouracil, etoposide or combinations therein. This ... are not able to reach in a sufficient ... that are not harmful to the rest of ...
Breaking Medicine News(10 mins):Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 2Health News:Aspirus Wausau Hospital Announces First Large Scale Digital Operating Room Integration Project in the US 3Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 2Health News:Global Market for Advanced Orthopedic Technology to Reach $42.2 Billion in 2019; Biotechnological Advancements Driving the Market 3Health News:UniWigs Is Offering A Big Sale for Labor Day on All Its Products 2Health News:Hormone Might Help Preemies' Brains 2Health News:Hormone Might Help Preemies' Brains 3Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 2Health News:The thunder god vine, assisted by nanotechnology, could shake up future cancer treatment 3
... , it could be causing gut inflammation, study suggests, , ... in the mouth, skin and intestines might play a role ... study says. , Researchers found the bacterium ... all babies in their study who had colic, a condition ...
... N.J., Aug. 6 Vitamin Shoppe Industries Inc., a leading ... products, will hold a conference call for its bondholders on ... the call, members of management will report on the Company,s ... To participate in the teleconference, bondholders are invited to ...
... , , Truth-teller Wendell Potter Asks ... SANTA MONICA, Calif., Aug. 6 The following is being released ... public messages to federal Office of Reform chief Nancy Ann DeParle, insurance ... Angeles stadium next week where medical volunteers will offer health care services ...
... Preventive measures urgently needed, researcher says , THURSDAY, Aug. 6 ... bone fracture is doubled for people who have a stroke, ... need for immediate preventive action after a stroke, said Frank ... of Utrecht, and lead author of a report that appears ...
... Experiment shows that these birds can use tools to solve problems ... shows. , A U.K. study found that the members of the ... of water in a container to bring a floating worm within ... study showed a high degree of accuracy, using only the exact ...
... , PHOENIX, Aug. 6 NutraCea ... bran nutrient research and technology, today announced the Company has entered ... Fargo") relating to the previously disclosed "Events of Default" which accelerated ... 18, 2008. , , Pursuant to the ...
Cached Medicine News:Health News:Bacteria May Be Connected to Colic 2Health News:Health Insurance Whistleblower Urges Obama Health Chiefs to Join Him at Free Urban Health Care 'Expedition' in L.A. Stadium 2Health News:Health Insurance Whistleblower Urges Obama Health Chiefs to Join Him at Free Urban Health Care 'Expedition' in L.A. Stadium 3Health News:Health Insurance Whistleblower Urges Obama Health Chiefs to Join Him at Free Urban Health Care 'Expedition' in L.A. Stadium 4Health News:Health Insurance Whistleblower Urges Obama Health Chiefs to Join Him at Free Urban Health Care 'Expedition' in L.A. Stadium 5Health News:Health Insurance Whistleblower Urges Obama Health Chiefs to Join Him at Free Urban Health Care 'Expedition' in L.A. Stadium 6Health News:Stroke Doubles Risk of Hip, Thigh Fractures 2Health News:Stroke Doubles Risk of Hip, Thigh Fractures 3Health News:Rooks Show Intelligence in Catching the Worm 2Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 2Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 3Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 4Health News:NutraCea Announces Forbearance Agreement With Bank and Provides Update on Business Strategy and Transactions 5
... Cascade M-4 is a manual ... all routine clotting assays - PTs, ... Designed for easy, inexpensive, low-volume testing, ... but big on features, offering time ...
... a fully automated, benchtop coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
The CA-50 is a compact semi-automated coagulation analyzerproviding 4-parameter random access....
... The ACL 100 is an ... workloads, or as a backup ... runs clotting assays, such as ... it's backed by superior technology ...
Medicine Products: